Tags

Type your tag names separated by a space and hit enter

Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
Pediatr Hematol Oncol. 2010 Oct; 27(7):529-33.PH

Abstract

High-dose Busulfan in combination chemotherapy has been used commonly for hematopoietic stem cell transplantation. It crosses the blood-brain barrier and could cause seizure. Benzodiazepines have been used as anticonvulsant prophylaxis. This is a prospective study using oral lorazepam together with busulfan-based conditioning regimen in 30 children undergoing hematopoietic stem cell transplantation. The dose of lorazepam used ranged from 0.017 to 0.039 mg/kg (median = 0.026 mg/kg) per dose. None of the patients developed seizure while receiving oral lorazepam or within 72 hours of the last dose of Busulfan. Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects. In the authors' experience, oral lorazepam is a useful anticonvulsant prophylaxis for children receiving high-dose busulfan.

Authors+Show Affiliations

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20677921

Citation

Hamidieh, Amir Ali, et al. "Oral Lorazepam Prevents Seizure During High-dose Busulfan in Children Undergoing Hematopoietic Stem Cell Transplantation: a Prospective Study." Pediatric Hematology and Oncology, vol. 27, no. 7, 2010, pp. 529-33.
Hamidieh AA, Hamedani R, Hadjibabaie M, et al. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatr Hematol Oncol. 2010;27(7):529-33.
Hamidieh, A. A., Hamedani, R., Hadjibabaie, M., Amini, M., Sadrai, S., & Ghavamzadeh, A. (2010). Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatric Hematology and Oncology, 27(7), 529-33. https://doi.org/10.3109/08880018.2010.496895
Hamidieh AA, et al. Oral Lorazepam Prevents Seizure During High-dose Busulfan in Children Undergoing Hematopoietic Stem Cell Transplantation: a Prospective Study. Pediatr Hematol Oncol. 2010;27(7):529-33. PubMed PMID: 20677921.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. AU - Hamidieh,Amir Ali, AU - Hamedani,Ravak, AU - Hadjibabaie,Molouk, AU - Amini,Mohsen, AU - Sadrai,Sima, AU - Ghavamzadeh,Ardeshir, PY - 2010/8/4/entrez PY - 2010/8/4/pubmed PY - 2011/2/12/medline SP - 529 EP - 33 JF - Pediatric hematology and oncology JO - Pediatr Hematol Oncol VL - 27 IS - 7 N2 - High-dose Busulfan in combination chemotherapy has been used commonly for hematopoietic stem cell transplantation. It crosses the blood-brain barrier and could cause seizure. Benzodiazepines have been used as anticonvulsant prophylaxis. This is a prospective study using oral lorazepam together with busulfan-based conditioning regimen in 30 children undergoing hematopoietic stem cell transplantation. The dose of lorazepam used ranged from 0.017 to 0.039 mg/kg (median = 0.026 mg/kg) per dose. None of the patients developed seizure while receiving oral lorazepam or within 72 hours of the last dose of Busulfan. Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects. In the authors' experience, oral lorazepam is a useful anticonvulsant prophylaxis for children receiving high-dose busulfan. SN - 1521-0669 UR - https://www.unboundmedicine.com/medline/citation/20677921/Oral_lorazepam_prevents_seizure_during_high_dose_busulfan_in_children_undergoing_hematopoietic_stem_cell_transplantation:_a_prospective_study_ L2 - https://www.tandfonline.com/doi/full/10.3109/08880018.2010.496895 DB - PRIME DP - Unbound Medicine ER -